Clinical trial
Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in…
NCT00079066 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00079066 |
|---|---|
| Title | Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer |
| Official title | A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Collaborators | Australasian Gastro-Intestinal Trials Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Quality of Life |
| Intervention type | Biological, Procedure |
| Interventions | cetuximab, quality-of-life assessment |
| Enrollment | 572 |
| Start date | Dec 30, 2003 |
| Primary completion | Nov 3, 2006 |
| Completion | Feb 10, 2009 |
| First posted | Mar 9, 2004 |
| Last update posted | Aug 4, 2023 |
| Countries | Australia, Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: